Table 3.
Associations between aspirin and non-aspirin NSAID use and risk of ovarian cancer by COX1/COX2 level in the Nurses’ Health Studies and the New England Case Control Study
| OR (95% CI) | OR (95% CI) | |||||||
|---|---|---|---|---|---|---|---|---|
| Controls (n) | Cases (n) | COX1− | COX1+ | P-het | COX2− | COX2+ | P-het | |
| Aspirin | ||||||||
| Regular use | ||||||||
| No regular use | 1552 | 197 | (ref) | (ref) | (ref) | (ref) | ||
| Past use | 280 | 92 | 0.74 (0.49, 1.11) | 0.87 (0.50, 1.49) | 0.79 (0.52, 1.19) | 0.78 (0.47, 1.28) | ||
| Recent use | 605 | 163 | 0.71 (0.50, 1.01) | 0.87 (0.54, 1.38) | 0.82 (0.57, 1.17) | 0.68 (0.44, 1.06) | ||
| 0.72 | 0.73 | |||||||
| Duration | ||||||||
| <1 year | 1616 | 212 | (ref) | (ref) | (ref) | (ref) | ||
| 1 to <5 years | 206 | 39 | 0.68 (0.43, 1.09) | 0.72 (0.36, 1.44) | 0.67 (0.41, 1.09) | 0.75 (0.40, 1.38) | ||
| 5 to <10 years | 197 | 62 | 0.95 (0.62, 1.45) | 0.96 (0.53, 1.77) | 1.14 (0.75, 1.73) | 0.67 (0.36, 1.24) | ||
| 10+ years | 347 | 109 | 0.76 (0.51, 1.13) | 0.95 (0.57, 1.59) | 0.92 (0.62, 1.37) | 0.70 (0.42, 1.17) | ||
| p-trend | 0.34 | 0.92 | 0.91 | 0.22 | ||||
| 0.46 | 0.22 | |||||||
| Tablets | ||||||||
| <1 tablet/week | 1728 | 260 | (ref) | (ref) | (ref) | (ref) | ||
| 1 to <6 tablets/week | 395 | 131 | 0.91 (0.66, 1.25) | 0.94 (0.61, 1.46) | 0.90 (0.65, 1.24) | 1.01 (0.67, 1.53) | ||
| 6+ tablets per week | 292 | 62 | 0.76 (0.52, 1.13) | 0.87 (0.51, 1.49) | 0.82 (0.56, 1.22) | 0.79 (0.46, 1.34) | ||
| p-trend | 0.17 | 0.62 | 0.31 | 0.40 | ||||
| 0.69 | 0.95 | |||||||
| Non-aspirin NSAIDs | ||||||||
| Regular use | ||||||||
| No regular use | 1600 | 208 | (ref) | (ref) | (ref) | (ref) | ||
| Past use | 247 | 105 | 1.54 (1.08, 2.20) | 1.50 (0.91, 2.47) | 1.71 (1.19, 2.44) | 1.27 (0.79, 2.04) | ||
| Recent use | 460 | 110 | 0.96 (0.68, 1.34) | 1.05 (0.66, 1.68) | 1.00 (0.70, 1.41) | 1.00 (0.65, 1.53) | ||
| 0.92 | 0.55 | |||||||
| Duration | ||||||||
| <1 year | 1680 | 226 | (ref) | (ref) | (ref) | (ref) | ||
| 1 to <5 years | 347 | 84 | 0.92 (0.64, 1.31) | 1.03 (0.63, 1.68) | 1.12 (0.79, 1.60) | 0.67 (0.40, 1.11) | ||
| 5 to <10 years | 206 | 72 | 1.27 (0.86, 1.88) | 1.21 (0.70, 2.11) | 1.38 (0.93, 2.06) | 1.09 (0.65, 1.83) | ||
| 10+ years | 111 | 45 | 1.75 (1.08, 2.82) | 1.92 (0.99, 3.72) | 1.59 (0.95, 2.68) | 2.24 (1.28, 3.93) | ||
| p-trend | 0.010 | 0.05 | 0.02 | 0.006 | ||||
| 0.93 | 0.51 | |||||||
| Tablets | ||||||||
| <1 tablet/week | 1478 | 184 | (ref) | (ref) | (ref) | (ref) | ||
| 1 to <6 tablets/week | 164 | 50 | 0.96 (0.59, 1.54) | 1.45 (0.78, 2.70) | 0.87 (0.51, 1.48) | 1.49 (0.87, 2.55) | ||
| 6+ tablets per week | 225 | 48 | 1.03 (0.65, 1.61) | 1.07 (0.55, 2.09) | 1.01 (0.63, 1.64) | 1.08 (0.60, 1.92) | ||
| p-trend | 0.97 | 0.77 | 0.95 | 0.71 | ||||
| 0.82 | 0.74 | |||||||
Models are adjusted for: cohort, age, menopausal status (pre/post), parity (nulliparous, 1, 2, 3, >3), oral contraceptive use (<1, 1-5, 5-10, 10+ years), estrogen, estrogen+progestin and other HT use (ever/never), tubal ligation (yes/no), hysterectomy (yes/no), family history of breast or ovarian cancer (yes/no), and BMI (<20, 20-25, 25-30, 30+)